| __timestamp | Johnson & Johnson | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 22746000000 | 5758000 |
| Thursday, January 1, 2015 | 21536000000 | 8423000 |
| Friday, January 1, 2016 | 21685000000 | 11986000 |
| Sunday, January 1, 2017 | 25354000000 | 15215000 |
| Monday, January 1, 2018 | 27091000000 | 15356000 |
| Tuesday, January 1, 2019 | 27556000000 | 16660000 |
| Wednesday, January 1, 2020 | 28427000000 | 52459000 |
| Friday, January 1, 2021 | 23402000000 | 75061000 |
| Saturday, January 1, 2022 | 24596000000 | 87221000 |
| Sunday, January 1, 2023 | 26553000000 | 83779000 |
| Monday, January 1, 2024 | 27471000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical landscape, understanding cost structures is pivotal. From 2014 to 2023, Johnson & Johnson's cost of revenue showcased a steady climb, peaking in 2020 with a 25% increase from 2014. This reflects their robust market presence and strategic investments. In contrast, Supernus Pharmaceuticals, Inc. experienced a dramatic surge, with costs skyrocketing by over 1,300% during the same period, highlighting their aggressive expansion and scaling efforts.
These insights provide a window into the strategic maneuvers of these industry giants, offering a glimpse into their operational priorities and market strategies.
Eli Lilly and Company vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Johnson & Johnson vs Regeneron Pharmaceuticals, Inc.
Johnson & Johnson vs Viatris Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Johnson & Johnson and Cytokinetics, Incorporated's Expenses
Johnson & Johnson vs Agios Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.
Biogen Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Jazz Pharmaceuticals plc and Supernus Pharmaceuticals, Inc.
Cost Insights: Breaking Down Lantheus Holdings, Inc. and Supernus Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Trends: ADMA Biologics, Inc. vs Supernus Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Supernus Pharmaceuticals, Inc. and Xencor, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.'s Expenses